These results are in keeping with the findings of a cohort study reported in 2016, where 90 ALK-positive NSCLC patients with BMs at baseline showed a median OS of 49.5 months (95% CI 29.0–not reached) despite a median intracranial PFS of 11.9 months (95% CI 10.1–18.2) [38]. Here, ALK is linked to non-small cell lung carcinoma.